

Hirofumi Yoshino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5014986/publications.pdf>

Version: 2024-02-01

36
papers

1,955
citations

331670

21
h-index

345221

36
g-index

37
all docs

37
docs citations

37
times ranked

3130
citing authors

#	ARTICLE	IF	CITATIONS
1	Aberrant expression of microRNAs in bladder cancer. <i>Nature Reviews Urology</i> , 2013, 10, 396-404.	3.8	200
2	Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. <i>Oncotarget</i> , 2012, 3, 44-57.	1.8	173
3	The MicroRNA Expression Signature of Bladder Cancer by Deep Sequencing: The Functional Significance of the miR-195/497 Cluster. <i>PLoS ONE</i> , 2014, 9, e84311.	2.5	142
4	Tumor suppressive microRNA-143/145 cluster targets hexokinase 2 in renal cell carcinoma. <i>Cancer Science</i> , 2013, 104, 1567-1574.	3.9	118
5	Dual tumor suppressors miR-139-5p and miR-139-3p targeting matrix metalloproteinase 13 in bladder cancer. <i>Cancer Science</i> , 2016, 107, 1233-1242.	3.9	115
6	The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. <i>Journal of Human Genetics</i> , 2014, 59, 78-87.	2.3	112
7	Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): inhibition of bladder cancer cell aggressiveness. <i>Oncotarget</i> , 2016, 7, 28460-28487.	1.8	93
8	Tumor suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma. <i>Cancer Science</i> , 2013, 104, 304-312.	3.9	87
9	Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. <i>Journal of Human Genetics</i> , 2013, 58, 508-516.	2.3	78
10	Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 588-593.	2.1	77
11	The role of microRNAs in bladder cancer. <i>Investigative and Clinical Urology</i> , 2016, 57, S60.	2.0	75
12	miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. <i>International Journal of Oncology</i> , 2011, 39, 13-21.	3.3	73
13	The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 59070-59086.	1.8	66
14	PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2 α -Targeting Therapy for Renal Cell Carcinoma. <i>Cancer Research</i> , 2017, 77, 6321-6329.	0.9	60
15	microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 20881-20894.	1.8	57
16	Expression of the Tumor Suppressive miRNA-23b/27b Cluster is a Good Prognostic Marker in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 1822-1830.	0.4	52
17	Tumour-suppressive microRNA-24-1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer. <i>FEBS Letters</i> , 2014, 588, 3170-3179.	2.8	52
18	Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. <i>British Journal of Cancer</i> , 2017, 116, 1077-1087.	6.4	48

#	ARTICLE	IF	CITATIONS
19	Potential new therapy of Rapalink ¹ , a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1607-1618.	3.9	38
20	Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. <i>Oncotarget</i> , 2018, 9, 23003-23017.	1.8	28
21	Potential tumor-suppressive role of microRNA-99a-3p in sunitinib-resistant renal cell carcinoma cells through the regulation of RRM2. <i>International Journal of Oncology</i> , 2019, 54, 1759-1770.	3.3	24
22	HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. <i>International Journal of Oncology</i> , 2018, 53, 725-736.	3.3	22
23	Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2020, 15, e0236119.	2.5	20
24	Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant. <i>PLoS ONE</i> , 2020, 15, e0232545.	2.5	19
25	EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 48.	2.6	19
26	Downregulation of microRNA-1274a induces cell apoptosis through regulation of BMPR1B in clear cell renal cell carcinoma. <i>Oncology Reports</i> , 2017, 39, 173-181.	2.6	18
27	Dynamic compartmentalization of purine nucleotide metabolic enzymes at leading edge in highly motile renal cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 50-56.	2.1	17
28	Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation. <i>Molecular Oncology</i> , 2020, 14, 2190-2202.	4.6	17
29	Tumor-suppressive microRNA-223 targets WDR62 directly in bladder cancer. <i>International Journal of Oncology</i> , 2019, 54, 2222-2236.	3.3	16
30	microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1. <i>Molecular Oncology</i> , 2022, 16, 1329-1346.	4.6	13
31	Anatomical Variations of the Left Renal Vein During Laparoscopic Donor Nephrectomy. <i>Transplantation Proceedings</i> , 2019, 51, 1311-1313.	0.6	6
32	Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 66-72.	1.3	5
33	Is It Safe to Use the Same Scissors After Accidental Tumor Incision During Partial Nephrectomy? Results of <i>In Vitro</i> and <i>In Vivo</i> Experiments. <i>Journal of Endourology</i> , 2017, 31, 391-395.	2.1	4
34	Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2022, 611, 99-106.	2.1	4
35	Oral Propranolol in a Child With Infantile Hemangioma of the Urethra. <i>Urology</i> , 2018, 122, 165-168.	1.0	3
36	Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery. <i>Investigative and Clinical Urology</i> , 2021, 62, 166.	2.0	0